Business
Atea Announces Presentation of Bemnifosbuvir Data Demonstrating Reduced Hospitalizations for COVID-19 Patients at 2023 European Congress of Clinical Microbiology & Infectious Diseases
71% reduction in risk of hospitalization for mild to moderate COVID-19 outpatients treated with bemnifosbuvir versus placebo in MORNINGSKY study, regardless
About this update from Atea Pharmaceuticals, Inc.
[{"type":"text","content":"71% reduction in risk of hospitalization for mild to moderate COVID-19 outpatients treated with bemnifosbuvir versus placebo in MORNINGSKY study, regardless of vaccination status\nBOSTON, April 12, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral direct acting therapeutics for serious viral diseases, today announced the presentation of the full results from the MORNINGSKY Phase 3 trial evaluating bemnifosbuvir for the treatment of COVID-19. These results are being presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), which is taking place April 15-18, 2023 in Copenhagen, Denmark. Bemnifosbuvir is an investigational, oral, direct-acting antiviral being developed for the treatment of COVID-19. “With MORNINGSKY, in both low- and high-risk patients receiving bemnifosbuvir regardless of vaccination status, we see lower rates of hospitalization which is a clinically meaningful outcome,” said Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals. “The MORNINGSKY data also highlight additional potential clinical benefits of bemnifosbuvir. We believe these data, together with bemnifosbuvir’s favorable safety and drug-drug interaction profile, underscore its potential to address key unmet medical needs and limitations of current therapies for the treatment of COVID-19.” The MORNINGSKY results showed that non-hospitalized adult and adolescent patients receiving bemnifosbuvir for the treatment of mild to moderate COVID-19 experienced a 71% relative reduction in risk of hospitalization, regardless of vaccination status. In an exploratory analysis, an 82% reduction for hospitalization was seen in a subset of patients greater than 40 years of age. Topline results from the MORNINGSKY study were announced in May 2022. Although the MORNINGSKY Phase 3 trial did not meet its primary endpoint of improved time for alleviation of COVID-19 symptoms, it was observed that patients treated with bemnifosbuvir experienced lower rates of hospitalization, medically attended visits, COVID-19-related complications and post treatment infections compared to patients receiving placebo. In this trial, bemnifosbuvir was generally safe and well tolerated, and there were no...